Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €5.45 EUR
Change Today -0.04 / -0.73%
Volume 263.0
TXCL On Other Exchanges
EN Paris
As of 3:56 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

txcell (TXCL) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/2/14 - €8.10
52 Week Low
10/16/14 - €4.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TXCELL (TXCL)

Related News

No related news articles were found.

txcell (TXCL) Related Businessweek News

No Related Businessweek News Found

txcell (TXCL) Details

TxCell Promesses develops cell-based immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases. The company’s product candidates include OvaSave, which has completed phase I/II clinical trials for the treatment of severe refractory Crohn’s disease; and Col-Treg, which is under preclinical stage for the treatment of autoimmune uveitis. Its other product candidates include Myelin that is under development for the treatment of central nervous system inflammatory diseases; and HSP60, which is under development for the treatment of autoimmune and inflammatory diseases. The company was formerly known as TxCell S.A. and changed its name to TxCell Promesses in April 2014. TxCell Promesses was founded in 2001 and is headquartered in Valbonne, France.

42 Employees
Last Reported Date: 04/10/15
Founded in 2001

txcell (TXCL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

txcell (TXCL) Key Developments

TxCell Promesses Reports Revenue Results for the First Quarter of 2015

TxCell Promesses reported revenue results for the first quarter of 2015. For the quarter, the company generated revenues of €195,000, compared with revenues of €81,000 during the same period in 2014. The revenue for the first quarter of 2015 corresponds to €81,000 relating to amortization until December 31, 2016 of the payment received upon signature in 2013 of the partnership with Trizell/Ferring concerning Ovasave and €114,000 for income related to the financing by Trizell of the process and manufacturing development of Ovasave for TxCell’s future phase III clinical study and commercialization.

TxCell SA Announces Management Changes

TxCell SA announced the appointment of Stéphane Boissel as Chief Executive Officer (CEO). In addition, Dr. Miguel Forte, previously SVP Clinical and Regulatory, is promoted to Chief Operating Officer. Stéphane Boissel succeeds Damian Marron, who has resigned from the company to pursue other interests. One of the main initial tasks for Stéphane will be to continue to strengthen the visibility of TxCell within the investment community, specifically in the US and the EU, and to continue to develop TxCell through its pipeline of products and partnerships. Specifically, Stéphane will continue to develop the exclusive worldwide license option agreement signed by Ferring International Center (SA) (Ferring) and TxCell in December 2013 for development of TxCell’s lead product Ovasave for the treatment of Inflammatory Bowel Diseases (IBD), including Crohn's disease and ulcerative colitis. Dr. Miguel Forte will focus directly on the development of the TxCell product portfolio and the supply chain. Ovasave, TxCell’s lead product, is currently in a phase IIb clinical trial for refractory Crohn’s disease (CATS29 study – see release of Dec. 4, 2014). Top line results of this study are expected at the end of 2016, early 2017. Miguel will also continue to develop Col-Treg, its second product candidate from its ASTrIA platform. Col-Treg is set to start a phase I/II proof of principle clinical study in autoimmune uveitis mid-2015. Stéphane Boissel is a highly capable executive with strong experience in both investment banking and the biotech immunotherapy space. Prior to joining TxCell, Stéphane was CEO of Genclis, a molecular diagnostic company. In addition to his role as COO of TxCell, Miguel Forte is also Chair of the Commercialisation Committee for the International Society of Cellular Therapy, and a Fellow of the Faculty of Pharmaceutical Medicine of the RCP (UK). Appointed to TxCell as CMO in 2010, Miguel brought 17 years of broad pharmaceutical industry experience from UCB, Nabi Pharmaceuticals, Bristol-Myers Squibb and the European Medicines Agency.

Trizell Holding SA and Trizell Holding SA Amend Collaboration Agreement to Accelerate Ovasave Development

Trizell Holding SA announced an amendment to the Ovasave collaboration option, development and license agreement (Ovasave Agreement) with Trizell Holding SA (Trizell). In the agreement, TxCell will undertake a program to bring forward the preparation of Ovasave for phase 3 development and commercialization, notably in the areas of process and manufacturing development. To finance this program, Trizell will advance up to €1.1 million in funding that was initially due after the future exercise of Trizell’s option to Ovasave. In Trizell’s sole discretion it may finance a further €4.3 million. TxCell has appointed the Cell Therapy Catapult, to undertake the process and manufacturing development of TxCell’s ASTrIA product platform under TxCell’s leadership. Ovasave, TxCell’s product, is currently in a phase IIb clinical trial for refractory Crohn’s disease. Top line results of this study are expected at the end of 2016 /early 2017. Initiating the program detailed in the latest amendment to the agreement is intended to enable Ovasave to be moved seamlessly into phase III development following the ongoing phase IIb study. It also aims to ensure that the phase III program is performed with the same cost-effective manufacturing processes that will be used for future commercial products. In addition, the process will be designed and automated to allow it to be easily and economically upscaled in line with future demand. The program allows other activities to be performed including formulation selection and any necessary pre-clinical studies. TxCell will own all results and intellectual property generated, which can be used across TxCell’s ASTrIA product platform. TxCell will grant Trizell an exclusive license to use the results and IP specifically for Ovasave in IBD (Inflammatory Bowel Diseases) in line with the Ovasave Agreement. Trizell has initially committed €1.1 million of funding to the phase III preparation program and may, in its sole discretion, commit up to a further €4.3 million. This funding will be offset against the potential total payments of up to €76 million due to TxCell under the Ovasave Agreement.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TXCL:FP €5.45 EUR -0.04

TXCL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TXCL.
View Industry Companies

Industry Analysis


Industry Average

Valuation TXCL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.1x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TXCELL, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at